Literature DB >> 28365890

Expressions of insulin-like growth factor receptor-1 and cezanne-1 in lung adenocarcinoma.

Zhaofei Pang1, Lixuan Cui1, Nan Ding1, Linhai Zhu2, Xiao Qu1, Wei Dong2, Jiajun Du3,4, Qi Liu5.   

Abstract

IGF1R (insulin-like growth factor receptor-1) was confirmed to play a significant role in the development of cancer. Cezanne-1 overexpression was considered to be associated with enhancement of EGFR signaling pathway and reduced degeneration of EGFR. There was a close relationship between EGFR and IGFR as previous study showed. Dynamic balance between receptor ubiquitination and deubiquitination was critical in the process of termination of IGF signaling pathway. So we conducted an IHC staining to initially prove the correlation. Cezanne-1 and IGF1R expressions were evaluated in 103 patients with lung adenocarcinoma using immunohistochemical (IHC) analysis. The relationship between expressions of cezanne-1 and IGF1R were analyzed by χ2 test. Kaplan-Meier method was used to generate the survival curve, and the statistical difference was calculated by log-rank test. We also used data in R2 system to verify the relationship between IGF1R and cezanne-1. R2 system showed there was a close correlation between IGF1R and cezanne-1. Positive expression of cezanne-1 was detected in 64.1% patients. A significant association was shown between cezanne-1 and IGF1R expression (p < 0.001). Multivariate analysis confirmed that both cezanne-1 and IGF1R expressions were independent prognostic factors for OS. (HR 2.96, 95% CI 1.090-8.060, p = 0.033; HR 2.273, 95% CI 1.016-5.085, p = 0.046, respectively). Our findings indicated both cezanne-1 and IGF1R expressions were negative independent predictive factors for the prognosis of lung adenocarcinoma, respectively. There was a close positive interrelationship between cezanne-1 and IGF1R expression.

Entities:  

Keywords:  Cezanne-1; Insulin-like growth factor receptor-1; Lung adenocarcinoma; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28365890     DOI: 10.1007/s12032-017-0934-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.

Authors:  Young Hak Kim; Shinji Sumiyoshi; Seiji Hashimoto; Katsuhiro Masago; Yosuke Togashi; Yuichi Sakamori; Chiyuki Okuda; Tadashi Mio; Michiaki Mishima
Journal:  Clin Lung Cancer       Date:  2012-01-28       Impact factor: 4.785

2.  Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Authors:  Aung Naing; Razelle Kurzrock; Angelika Burger; Sachin Gupta; Xiudong Lei; Naifa Busaidy; David Hong; Helen X Chen; Lawrence A Doyle; Lance K Heilbrun; Eric Rohren; Chaan Ng; Chandtip Chandhasin; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

Review 3.  Breaking the chains: structure and function of the deubiquitinases.

Authors:  David Komander; Michael J Clague; Sylvie Urbé
Journal:  Nat Rev Mol Cell Biol       Date:  2009-08       Impact factor: 94.444

Review 4.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

5.  Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne.

Authors:  Anja Bremm; Stefan M V Freund; David Komander
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

6.  Co-expression of β-arrestin1 and NF-кB is associated with cancer progression and poor prognosis in lung adenocarcinoma.

Authors:  Jianyu Yu; Liguang Wang; Tiehong Zhang; Hongchang Shen; Wei Dong; Yang Ni; Jiajun Du
Journal:  Tumour Biol       Date:  2015-03-28

7.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

Authors:  A V Lee; J G Jackson; J L Gooch; S G Hilsenbeck; E Coronado-Heinsohn; C K Osborne; D Yee
Journal:  Mol Endocrinol       Date:  1999-05

8.  Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression.

Authors:  F Pareja; D A Ferraro; C Rubin; H Cohen-Dvashi; F Zhang; S Aulmann; N Ben-Chetrit; G Pines; R Navon; N Crosetto; W Köstler; S Carvalho; S Lavi; F Schmitt; I Dikic; Z Yakhini; P Sinn; G B Mills; Y Yarden
Journal:  Oncogene       Date:  2011-12-19       Impact factor: 9.867

9.  High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

Authors:  Yixuan Gong; Evelyn Yao; Ronglai Shen; Aviva Goel; Maria Arcila; Julie Teruya-Feldstein; Maureen F Zakowski; Stanley Frankel; Martin Peifer; Roman K Thomas; Marc Ladanyi; William Pao
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

10.  Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Authors:  V M Macaulay; M R Middleton; A S Protheroe; A Tolcher; V Dieras; C Sessa; R Bahleda; J-Y Blay; P LoRusso; D Mery-Mignard; J-C Soria
Journal:  Ann Oncol       Date:  2012-10-26       Impact factor: 32.976

View more
  7 in total

1.  Cezanne contributes to cancer progression by playing a key role in the deubiquitination of IGF-1R.

Authors:  Xiaowei Chen; Zhaofei Pang; Yu Wang; Linhai Zhu; Jichang Liu; Jiajun Du
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Glucose-Restricted Diet Regulates the Tumor Immune Microenvironment and Prevents Tumor Growth in Lung Adenocarcinoma.

Authors:  Alexander Gähler; Denis I Trufa; Mircea T Chiriac; Patrick Tausche; Katja Hohenberger; Ann-Kathrin Brunst; Manfred Rauh; Carol I Geppert; Ralf J Rieker; Susanne Krammer; Anna Leberle; Markus F Neurath; Horia Sirbu; Arndt Hartmann; Susetta Finotto
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

3.  Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.

Authors:  Dan-Dan Lin; Yang Shen; Shu Qiao; Wen-Wen Liu; Lishuang Zheng; Ya-Nan Wang; Naipeng Cui; Yun-Fan Wang; Shuli Zhao; Jian-Hong Shi
Journal:  Front Oncol       Date:  2019-09-11       Impact factor: 6.244

Review 4.  Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-α Subunit Abundance.

Authors:  Kateryna Kubaichuk; Thomas Kietzmann
Journal:  Cells       Date:  2019-06-15       Impact factor: 6.600

5.  Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma.

Authors:  Shi Qiu; Yizhen Liu; Ailing Gui; Zuguang Xia; Wen Liu; Juan J Gu; Ji Zuo; Ling Yang; Qunling Zhang
Journal:  J Cancer       Date:  2022-01-04       Impact factor: 4.207

6.  Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway.

Authors:  Shan Lei; Zhiwei He; Tengxiang Chen; Xingjun Guo; Zhirui Zeng; Yiyi Shen; Jianxin Jiang
Journal:  J Exp Clin Cancer Res       Date:  2019-11-20

7.  Multi-Omics Data Analysis Uncovers Molecular Networks and Gene Regulators for Metabolic Biomarkers.

Authors:  Su Yon Jung
Journal:  Biomolecules       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.